Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FULC
stocks logo

FULC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.324
+4.52%
--
--
-0.307
+9.82%
--
--
-0.303
+8.33%
Estimates Revision
The market is revising No Change the revenue expectations for Fulcrum Therapeutics, Inc. (FULC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 14.36%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.28%
In Past 3 Month
Stock Price
Go Up
up Image
+14.36%
In Past 3 Month
Wall Street analysts forecast FULC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FULC is 14.50 USD with a low forecast of 6.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast FULC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FULC is 14.50 USD with a low forecast of 6.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
1 Sell
Moderate Buy
Current: 8.760
sliders
Low
6.00
Averages
14.50
High
20.00
Current: 8.760
sliders
Low
6.00
Averages
14.50
High
20.00
Truist
initiated
$14
2025-11-24
Reason
Truist
Price Target
$14
2025-11-24
initiated
Reason
Truist initiated coverage of Fulcrum Therapeutics with a Buy rating and $14 price target. Fulcrum Therapeutics has shown early signs that pociredir could be competitive in the SCD therapeutic landscape, the analyst tells investors in a research note. Encouraging data from the phase Ib PIONEER study for pociredir shows notable induction of HbF, most recently in patients dosed with 12 mg of drug, which in July showed robust and clinically meaningful absolute mean fetal hemoglobin HbF induction of 8.6% from baseline at 12 weeks, and safety continues to remain in-line with previous dosing cohorts and healthy volunteer data, the firm says.
Oppenheimer
Matthew Biegler
Outperform
maintain
2025-11-19
Reason
Oppenheimer
Matthew Biegler
Price Target
2025-11-19
maintain
Outperform
Reason
Oppenheimer analyst Matthew Biegler notes that Fulcrum Therapeutics' (FULC) shares are rallying this morning in the wake of Agios' (AGIO) failed RISE UP trial. Investors are likely viewing the outcome as removing a potential competitor to Fulcrum in sickle cell disease. Oppenheimer is not entirely surprised by the result. RISE UP ended up resembling HOPE: Marginal improvements in hemoglobin that trended but didn't reach statistical significance on vaso-occlusive crises. The firm continues to favor Fulcrum's approach, which induces fetal hemoglobin rather than indirectly modifying hemoglobin. There's simply more evidence translating HbF levels to clinical benefit in SCD. Fulcrum will present additional data from PIONEER at ASH, and Oppenheimer thinks that could cement its position as the go-to oral option of the future. The firm reiterates an Outperform rating on Fulcrum.
Stifel
analyst
initiated
$20
2025-11-06
Reason
Stifel
analyst
Price Target
$20
2025-11-06
initiated
Reason
Stifel resumed coverage of Fulcrum Therapeutics with a Buy rating and $20 price target. Recent 12mg data already support a "compelling profile" for pociredir and the "bar" for the full 20mg cohort is low, argues the analyst, who adds that there's "a blockbuster opportunity that supports meaningful upside" even as Fulcrum's trial population and criteria exists today.
Piper Sandler
Overweight
maintain
$16
2025-10-30
Reason
Piper Sandler
Price Target
$16
2025-10-30
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Fulcrum Therapeutics to $16 from $12.50 and keeps an Overweight rating on the shares. The firm notes Fulcrum will report 20mg pociredir data at ASH in December. Fulcrum disclosed that baseline HbF in the 12 patients enrolled was 7.1% mean. Piper is confident that 20mg pociredir will outperform the 12mg cohort across performance measures.
Oppenheimer
Oppenheimer
Outperform
maintain
$12 -> $15
2025-07-29
Reason
Oppenheimer
Oppenheimer
Price Target
$12 -> $15
2025-07-29
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Fulcrum Therapeutics to $15 from $12 and keeps an Outperform rating on the shares after the company read out 12-week results from the 12 mg cohort of its sickle cell drug pociredir. Alongside improvements in red cell health and VOC reductions, Oppenheimer thinks these data suggest pociredir may be the first drug since hydroxyurea to address all the consequences of SCD. With nearly half of patients achieving greater than20% total HbF, the firm thinks this is already a drug that will benefit the majority.
H.C. Wainwright
Neutral -> Buy
upgrade
$4 -> $12
2025-07-29
Reason
H.C. Wainwright
Price Target
$4 -> $12
2025-07-29
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Fulcrum Therapeutics to Buy from Neutral with a price target of $12, up from $4.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fulcrum Therapeutics Inc (FULC.O) is -7.18, compared to its 5-year average forward P/E of -6.07. For a more detailed relative valuation and DCF analysis to assess Fulcrum Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.07
Current PE
-7.18
Overvalued PE
1.41
Undervalued PE
-13.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.61
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.68
Undervalued EV/EBITDA
-5.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
48.64
Current PS
0.00
Overvalued PS
113.89
Undervalued PS
-16.62
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 6467.26% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 6467.26% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

FULC News & Events

Events Timeline

(ET)
2025-11-19
11:26:11
Fulcrum's pociredir demonstrates encouraging initial effectiveness compared to mitapivat, according to Leerink.
select
2025-10-29 (ET)
2025-10-29
07:05:16
Fulcrum Therapeutics Announces Q3 Earnings Per Share of 31 Cents, Exceeding Consensus Estimate of 29 Cents
select
2025-09-02 (ET)
2025-09-02
10:59:12
Cantor Fitzgerald Reports Strong Dose Response with Pociredir, According to Fulcrum Data
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedFulcrum to Showcase New Data from PIONEER Trial on Sickle Cell Disease

  • Upcoming Presentation: Fulcrum Therapeutics will present new clinical data from its PIONEER trial for Pociredir, an oral treatment for sickle cell disease, on December 7, 2025.

  • PIONEER Trial Details: The Phase 1b trial aims to increase fetal hemoglobin production to alleviate symptoms of sickle cell disease, with initial data showing promising results from the 12 mg dose cohort.

  • Clinical Outcomes: The 12 mg cohort demonstrated an 8.6% mean increase in fetal hemoglobin levels, with several patients achieving levels above 20%, which is linked to reduced vaso-occlusive crises.

  • Financial Status: Fulcrum ended Q3 2025 with $200.6 million in cash and equivalents, ensuring operational funding through 2028, while its stock price has fluctuated between $2.32 and $12.19 over the past year.

[object Object]
Preview
2.0
11-18Benzinga
Major Stocks Including Helmerich and Payne, Invivyd, and Home Depot Decline in Tuesday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures are down, with Dow futures dropping approximately 200 points on Tuesday morning.

  • Helmerich and Payne Inc: The company reported a fourth-quarter loss of 1 cent per share despite quarterly sales of $1.012 billion, leading to a 7% drop in its shares during pre-market trading.

  • Other Stocks Declining: Several other stocks, including Alpha Technology Group Ltd and Invivyd Inc, experienced significant declines in pre-market trading, with drops of 19% and 13.4%, respectively.

  • Home Depot's Performance: Home Depot's shares fell 2% after reporting worse-than-expected third-quarter adjusted EPS and lowering its FY25 adjusted EPS outlook.

[object Object]
Preview
2.0
11-18Benzinga
Gorilla Technology Shares Rise Approximately 14%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Gorilla Technology Group Performance: Gorilla Technology Group Inc. reported a 32% year-over-year revenue increase to $26.5 million for Q3, leading to a 13.7% rise in its share price during pre-market trading.

  • Other Gainers in Pre-Market Trading: Notable stocks that surged include Olema Pharmaceuticals (up 53%), Lobo Technologies (up 40.3%), and Aspire Biopharma (up 30.7%), among others.

  • Losers in Pre-Market Trading: LifeMD Inc. saw a significant drop of 26.2% after disappointing financial results, while Alpha Technology Group and NextPlat Corp also experienced notable declines.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting strong earnings while others faced setbacks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fulcrum Therapeutics Inc (FULC) stock price today?

The current price of FULC is 8.76 USD — it has decreased -3.31 % in the last trading day.

arrow icon

What is Fulcrum Therapeutics Inc (FULC)'s business?

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.

arrow icon

What is the price predicton of FULC Stock?

Wall Street analysts forecast FULC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FULC is 14.50 USD with a low forecast of 6.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fulcrum Therapeutics Inc (FULC)'s revenue for the last quarter?

Fulcrum Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Fulcrum Therapeutics Inc (FULC)'s earnings per share (EPS) for the last quarter?

Fulcrum Therapeutics Inc. EPS for the last quarter amounts to -0.31 USD, decreased -11.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fulcrum Therapeutics Inc (FULC)'s fundamentals?

The market is revising No Change the revenue expectations for Fulcrum Therapeutics, Inc. (FULC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 14.36%.
arrow icon

How many employees does Fulcrum Therapeutics Inc (FULC). have?

Fulcrum Therapeutics Inc (FULC) has 45 emplpoyees as of December 05 2025.

arrow icon

What is Fulcrum Therapeutics Inc (FULC) market cap?

Today FULC has the market capitalization of 474.08M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free